New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
06:35 EDTNVSNovartis overhaul expected to improve core operating income margin
For its first "Meet Novartis Management" investor day, Novartis gathered more than 20 of its top executives to meet with approximately 100 investors and analysts in Basel. The conclusion of the portfolio review announced in April would create a new and more focused Novartis. Each of the three remaining businesses have both the innovation power to produce breakthroughs in areas of unmet medical need and the global scale to achieve growth across geographies - which is critical to winning in the changing healthcare landscape. The new Novartis is expected to be more profitable. Under the announced new structure, the Group's core operating income margin in 2013 would have been 27.2%, 250 basis points higher than the announced 24.7% on a pro forma basis. Through the creation of Novartis Business Services, Novartis is taking steps to improve profitability by generating synergies across businesses by harmonizing services across Group and divisions. The scope of NBS covers over $6B in expenses, and complements other ongoing productivity initiatives, including manufacturing footprint.Looking ahead, the Group's strategic priorities of innovation, growth and productivity remain unchanged. CEO Joseph Jimenez says, "Following the expected completion of the portfolio transformation transactions, the new Novartis will be more focused, more profitable, with the potential to grow faster."
News For NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
05:22 EDTNVSNovartis Cosentyx receives positive CHMP opinion
Subscribe for More Information
November 17, 2014
16:52 EDTNVSNovartis' LCZ696 could change course of heart failure for patients, study shows
New data on Novartis' investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction shows it has the potential to change the course of the disease for patients. In August, Novartis presented topline results from the landmark PARADIGM-HF study showing LCZ696 was superior to ACE inhibitor enalapril on key endpoints, including significantly reducing the risk of CV death or heart failure hospitalization. The new analyses being presented for the first time at the American Heart Association Scientific Sessions 2014, with a paper being simultaneously published in Circulation, show that versus enalapril, LCZ696 significantly: reduced the risk of dying suddenly by 20% in HFrEF patients 45% of CV deaths and 36% of all cause deaths are sudden; reduced first and subsequent HFrEF hospitalizations by 21% and 23% respectively; reduced hospitalizations for a cardiovascular reason or for any reason both by 16%; reduced the need for more intense treatment at home by 16%; reduced emergency room visits because of rapid symptom worsening by 30%.
11:06 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
November 16, 2014
15:07 EDTNVSNovartis says arthritis drug secukinumab met primary endpoint
Subscribe for More Information
November 14, 2014
14:53 EDTNVSCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
07:14 EDTNVSAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
13:32 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
November 12, 2014
11:17 EDTNVSLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:18 EDTNVSUBS to hold a conference
Subscribe for More Information
07:58 EDTNVSGenVec expects 2014 cash burn between $6M-$7M from Novartis collaboration
Subscribe for More Information
November 11, 2014
16:14 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
16:01 EDTNVSQIAGEN enters master collaboration agreement with Novartis
Subscribe for More Information
15:43 EDTNVSLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
16:07 EDTNVSUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
15:57 EDTNVSWorldwide Business Research to hold a conference
ProcureCon for Digital & Marketing Services 2014 is being held in San Antonio on November 11-13.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use